Article Details

KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to Sell at Zacks Investment Research

Retrieved on: 2022-03-12 12:09:32

Tags for this article:

Click the tags to see associated articles and topics

KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to Sell at Zacks Investment Research. View article details on hiswai:

Excerpt

Zacks Investment Research lowered KalVista Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday.

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up